School of Medicine


Showing 1-10 of 14 Results

  • Stephen Chang, MD, PhD

    Stephen Chang, MD, PhD

    Instructor, Biochemistry
    Instructor, Biochemistry
    Instructor, Medicine - Cardiovascular Medicine

    BioPrior to a career in medicine, Dr. Chang was an English major and subsequent novelist at night. During the days, he taught literature part-time at Rutgers University, and for extra money, worked in a laboratory in NYC washing test tubes. Inspired by his laboratory mentor, he began volunteering at the hospital next door, and developed a love for interacting with patients. Through this experience, he saw how caring for others could form deep bonds between people - even strangers - and connect us in a way that brings grandeur to ordinary life.

    In addition to seeing patients, Dr. Chang is a physician-scientist devoted to advancing the field of cardiovascular medicine. His research has been focused on identifying a new genetic organism that better models human heart disease than the mouse. For this purpose, he has been studying the mouse lemur, the smallest non-human primate, performing cardiovascular phenotyping (vital signs, ECG, echocardiogram) on lemurs both in-bred (in France) and in the wild (in Madagascar) to try to identify mutant cardiac traits that may be heritable - and in the process, characterize the first high-throughput primate model of human cardiac disease.

  • Ming Li (Estella) Chen

    Ming Li (Estella) Chen

    Postdoctoral Scholar, Cardiovascular Medicine

    BioI am an MD from Chung Shan Medical University, Taiwan. Before coming to Stanford, I obtained my MS degree in epidemiology at Harvard T.H. Chan School of Public Health, Boston, MA, where I completed graduate training in clinical, pharmacologic, and genetic epidemiology, and pursued advanced skills in biostatistics and causal inference.

    My past research focused on real-world epidemiology studies using patient registries and national health insurance databases to elucidate the predictors or risk factors of immunologic diseases. For my graduate study, I conducted pharmacoepidemiology studies using electronic health record (EHR) data to elucidate the predictors of anti-drug antibodies development and its correlation to autoimmunity, to identify the generation of immunogenicity that may impact the effectiveness of monoclonal antibody therapies in individuals with autoimmune diseases. I gained experience in genetic data manipulation to investigate polymorphisms in response to monoclonal antibody therapies in asthma patients.

    At Stanford, I am involved in research on the identification of molecular determinants of cardiometabolic diseases.

  • Paul Cheng MD PhD

    Paul Cheng MD PhD

    Assistant Professor of Medicine (Cardiovascular Medicine)

    BioDr. Cheng is a Cardiologist at Stanford University School of Medicine in the Department of Medicine and a member of the Cardiovascular Research Institute. Dr. Cheng received his BEng in Chemical Engineering and BSc in biology at MIT. He subsequently completed his MD/PhD at UCSF working in the Srivastava lab studying how extracellular morphogenic signals affect cardiac development and fate determination of cardiac progenitors. Dr. Cheng completed internal medicine residency and cardiology fellowship at Stanford. His current clinical focus is in amyloidosis and cardio-oncology. During his post doctoral research in the Quertermous lab, he pioneered the application of single cell transcriptomic and epigenetic techniques to study human vascular diseases including atherosclerosis and aneurysm, and applied these techniques to investigate molecular mechanisms behind genetic risk factors for several human vascular diseases including atherosclerosis, and aortopathies such as Marfan's and Loey-Dietz syndrome.

    The Cheng lab takes a patient-to-bench-to-bedside approach to science. The lab focuses on elucidating new pathogenic mechanisms of human vascular diseases through combing human genetics and primary vascular disease tissues, with high-resolution transcriptomic and epigenetic profiling to generate novel hypothesis that are then tested in a variety of in vitro and in vivo models. The lab is focused on two broad questions: (1) understanding the biological underpinning of the differences in diseases propensities of different arterial segments in an individual (i.e. why do you have atherosclerosis and aneurysms in certain segments but not others), and (2) understanding the role of perivascular fibroblast in human vascular diseases.

  • Daniel Clark, MD, MPH

    Daniel Clark, MD, MPH

    Clinical Assistant Professor, Medicine - Cardiovascular Medicine
    Clinical Assistant Professor, Pediatrics - Cardiology

    BioDr. Clark is a board-certified, fellowship-trained cardiologist with the Adult Congenital Heart Program at Stanford Health Care. He is also a clinical assistant professor with dual appointments in the Division of Cardiovascular Medicine, Department of Medicine and the Division of Cardiology, Department of Pediatrics at Stanford University School of Medicine.

    Dr. Clark specializes in the diagnosis and treatment of adult congenital heart disease (ACHD) and the management of congenital and acquired heart disease in children. His clinical focus involves the combined use of cardiac magnetic resonance (CMR) and other imaging techniques to evaluate patients with known or suspected cardiovascular disease. Dr. Clark’s extensive training and experience with these techniques include multiple fellowships in adult cardiology, cardiovascular imaging, and ACHD.

    Dr. Clark is currently a co-investigator on multiple research studies. During his fellowship, he received a training grant from the National Institutes of Health enabling evaluation of the ability of CMR to diagnose COVID-19-associated heart inflammation among college athletes. He currently uses CMR to assess heart transplant outcomes in donors positive for hepatitis C virus. Dr. Clark also received a research grant from the Adult Congenital Heart Disease Association supporting a randomized, controlled clinical trial of cardiac rehabilitation among patients with Fontan failure.

    Dr. Clark serves as a peer reviewer for multiple prestigious journals, including The New England Journal of Medicine, Circulation, Journal of the American College of Cardiology, and Journal of the American Heart Association (JAHA). He serves on the editorial board for both JAHA and Circulation: Cardiovascular Imaging. He is also a member of numerous professional medical societies, including the American College of Cardiology, the American Heart Association, and the Adult Congenital Heart Association.

  • Shoa L. Clarke, MD, PhD

    Shoa L. Clarke, MD, PhD

    Assistant Professor of Medicine (Cardiovascular Medicine) and of Pediatrics

    BioDr. Clarke is a preventive cardiologist and a physician-scientist focused on disease prevention. He earned his undergraduate degree in human biology from the Division of Nutritional Sciences at Cornell University before obtaining his MD and PhD (genetics) from Stanford University School of Medicine. He has completed clinical training in internal medicine (Brigham & Women’s Hospital), pediatrics (Boston Children’s Hospital), and cardiovascular medicine (Stanford Hospital), and he is board certified in all three specialties. His research is focused on 1) understanding complex disease genetics in diverse populations, 2) integrating monogenic and polygenic risk with clinical risk, 3) large-scale phenotyping using the electronic health record and medical images. His clinical practice focuses on identifying risk factors for cardiovascular disease with the goal of promoting health and longevity through evidence-based personalized treatment. He is interested in developing family-centric approaches for the treatment of adults and children carrying genetic risk for disease.